

Our commitment to sustainable development

As a science-led healthcare company, GSK has an important role to play in improving the health and well-being of millions of people around the world. We want to help people to do more, feel better and live long healthy lives, wherever they are in the world.



Since their inception in the year 2000 to help meet the needs of the world's poorest people, we have been contributing to the UN Millennium Development Goals (MDGs) on many fronts. As these goals evolve into the Sustainable Development Goals (SDGs), we continue to play our part. By this we mean developing our business in a way that takes into account social, economic and environmental considerations, and striving to create a world that is fair, equitable and inclusive for future generations.

The 17 SDGs span social, economic and environmental themes, including an aim to ensure healthy lives and promote well-being for all, at all ages.

A United Nations (UN) Open Working Group was formed in 2012 to develop the SDGs, the intention being to build on progress made under the MDGs.

GSK is fully committed to realising the post-2015 development agenda in a way that meets the shared goals of industry, governments and others, to expand patient access to medicines and services while preserving incentives for future innovation and sustainability. We do this by pursuing flexible business models focused on both innovation and access. These include open innovation approaches, tiered pricing and working in public-private partnerships.

Here we share our perspective on some of the health-related aims and provide examples of our contribution.

Achieve Universal Health Coverage (UHC)



Universal Health Coverage (UHC) is the idea that all people should receive quality health services that they need without experiencing financial hardship as a result. As part of our innovative partnership with Save the Children we are combining our voices to call for a thoughtful transition to UHC. We believe that there are eight core principles that should inform the design of UHC policies; equity, efficiency, quality, inclusiveness, evidence based decision-making, availability, affordability/funding and innovation.

Through our developing countries and Africa business unit, we are working to increase patient access to GSK medicines in developing countries, while ensuring that our business continues to be sustainable. Novel business models and flexible pricing help people get the vaccines and medicines they need. In the Least Developed Countries, GSK's patented medicine prices are capped at no more than 25% of their price in the UK – provided they cover our manufacturing costs.

GSK vaccines used in immunisation programmes in **170 countries**



End preventable deaths of newborns and children under-five



In May 2013 GSK embarked upon an innovative partnership with Save the Children to help save the lives of one million children. The partnership focuses on addressing the biggest gaps which result in child mortality by: widening immunisation coverage; addressing nutritional needs of children; and training health workers in the poorest communities.

One of the key innovations to be driven by this partnership is the development of a new gel formulation of chlorhexidine, found in a GSK mouthwash, that could help prevent umbilical cord infections in newborns. If assessed and approved by regulators, it could be used in poorer countries to apply to freshly cut umbilical cords.

This is just one element of our work to help save children's lives. Our vaccines are included in immunisation campaigns in 170 countries worldwide. In 2014, we delivered some 862 million vaccine doses, over 80% of them for use in developing countries. We continue our commitment to offer all our vaccines at reduced cost in developing countries using a tiered pricing system and our partnership with the GAVI Alliance provides newer vaccines to developing countries at reduced prices.

Support frontline health workers



Since 2009, GSK has reinvested 20% of the profits it generates in the UN-defined Least Developed Countries back into community programmes to help those countries strengthen health care infrastructure, primarily through training community health workers. Working with three NGO partners – CARE International, Amref Health Africa and Save the Children – we have now trained over 40,000 frontline health workers in 35 countries, reaching 11 million people and helping improve access to healthcare.

This initiative particularly focuses on training frontline health workers who are most critical to child and mother survival. This includes community health workers, midwives and nurses, who act as the first point of contact in remote areas, where the nearest health facility could be hours or even days away. We also educate and support communities to take greater ownership for managing their health.



40,000

frontline health workers trained in 35 countries

End the epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases (NTDs)



The biggest contribution we can make to combating diseases such as malaria and HIV/AIDS is through scientific innovation – researching and developing new treatments. In July 2015 our malaria vaccine candidate received a positive scientific opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa. The WHO is now assessing how the world's first malaria vaccine candidate might be used alongside other tools to prevent malaria.

We also worked closely with the WHO, regulators and other partners to respond to the Ebola crisis in 2014, contributing to the overall humanitarian effort as well as accelerating the development of our investigational Ebola vaccine. We have a long history at the frontline of researching innovative medicines to fight HIV. In 2009, GSK and Pfizer created ViiV Healthcare, a specialist HI company; Shionogi joined in 2012. Tivicay (dolutegravir) the first medicine from ViiV Healthcare's pipeline, was approved in the US in August 2013 and in Europe in January 2014.

Through an agreement with the Medicines Patent Pool (MPP), ViiV is accelerating access to dolutegravir where the need is the greatest, in the 121 countries where 99% of children and 93.4% of adults with HIV in the developing world live. Through its royalty-free voluntary licensing policy, the company also enables manufacturers of generic medicines to sell versions of its entire antiretroviral (ARV) portfolio.

As a leading partner of the London Declaration, GSK is working with the Bill & Melinda Gates Foundation, WHO, other pharmaceutical companies, donors and national governments to help control or eliminate 10 of the 17 NTDs that affect over 1 billion people by 2020. Our most significant contribution to this collective commitment is in the elimination of lymphatic filariasis (LF) and control of soil-transmitted helminths (intestinal worms). GSK has now donated more than five billion albendazole tablets to support these efforts; reaching over 600 million people, including 200 million children.

Support R&D of vaccines and medicines for diseases of developing countries



In 2014 we invested £3.2 billion in global research and development for innovative medicines, vaccines and consumer products. Developing medicines and vaccines for diseases that disproportionately affect developing countries and poorer populations remains a key focus for GSK.

Our dedicated drug discovery and development facility at Tres Cantos in Spain researches new treatments for diseases of the developing world (DDWs) such as TB and malaria. The open laboratory welcomes visiting scientists from universities, not-for-profits partnerships and other research institutes to work on projects for DDWs, learn from our expertise and share our world-class facilities. Since its establishment in 2010, scientists from a range of academic institutions around the world have joined our Open Lab, building a portfolio of 42 projects, 14 of which are now complete. Building on the success of Tres Cantos, GSK is also investing £25m to create the world's first R&D Open Lab for non-communicable diseases (NCDs) in Africa.



£3.2bn

invested global research and development

Reduce premature mortality from non-communicable diseases (NCDs)



Changing lifestyles and demographics mean that the global burden of NCDs is in the developing world with 80% of NCD-related deaths now occurring in low and middle-income countries. Tackling this significant challenge is an important focus for GSK and to do so, we have adopted a strategic approach to NCDs with a particular emphasis on developing countries. In 2014, we announced the creation of an 'open lab' dedicated to researching NCDs in Africa.

We have assets in clinical development for all four of the priority NCDs, and we are working to adapt our existing products to better meet the needs of patients in emerging markets. For example, we are conducting research on improving Flolan, our treatment for advanced stages of pulmonary arterial hypertension, to allow greater stability at higher temperatures.

Manage environmental impacts



Climate change is one of the world's most pressing issues and a major threat to people's health and global economic development.

By using resources more efficiently and collaborating with others to tackle these challenges, GSK has set ambitious goals to reduce carbon, water and waste across its value chain from the sourcing of raw materials and the impacts of its own labs and factories, to the use and disposal of its products by patients and consumers.

For example, through collaboration, more than 500 of our suppliers are sharing practical ideas to improve energy efficiency impacts through our online supplier exchange.

We are also making changes to chemical manufacturing processes. For example, our facility in Quality Road, Singapore uses enzymes in the manufacturing of amoxicillin (one of the most widely prescribed antibiotics in the world). This innovative process significantly cuts our carbon emissions by reducing cooling requirements, as well as producing less organic waste.



Read more about our progress
gsk.com/responsibility